|Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1|
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
autophagy 17 (1), 1-382, 2021
|Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine|
LR Baden, HM El Sahly, B Essink, K Kotloff, S Frey, R Novak, D Diemert, ...
New England Journal of Medicine 384 (5), 403-416, 2021
|Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant|
RS Sperling, DE Shapiro, RW Coombs, JA Todd, SA Herman, ...
New England Journal of Medicine 335 (22), 1621-1629, 1996
|Proceedings of the National Institutes of Health Consensus Development Conference Statement-Management of Hepatitis C, 10-12 June 2002|
National Institutes of Health
Hepatology 36, S3-S20, 2002
|1997USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus|
JE Kaplan, H Masur, KK Holmes, US Public Health Service, ...
MMWR Morb Mortal Wkly Rep 48, 1-59, 1999
|Guidelines for preventing opportunistic infections among HIV-infected persons—2002: recommendations of the US Public Health Service and the Infectious Diseases Society of America|
PH Masur, JE Kaplan, KK Holmes
Annals of internal medicine 137 (5_Part_2), 435-478, 2002
|The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo …|
MA Fischl, DD Richman, N Hansen, AC Collier, JT Carey, MF Para, ...
Annals of internal medicine 112 (10), 727-737, 1990
|Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections: Studies with …|
I Grant, JH ATKINSON, JR HESSELINK, CJ KENNEDY, DD RICHMAN, ...
Annals of internal medicine 107 (6), 828-836, 1987
|Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study|
WT Shearer, HM Rosenblatt, RS Gelman, R Oyomopito, S Plaeger, ...
Journal of Allergy and Clinical Immunology 112 (5), 973-980, 2003
|Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy|
DD Richman, D Havlir, J Corbeil, D Looney, C Ignacio, SA Spector, ...
Journal of virology 68 (3), 1660-1666, 1994
|A health status questionnaire using 30 items from the Medical Outcomes Study|
AW Wu, HR Rubin, WC Mathews, JE Ware Jr, LT Brysk, WD Hardy, ...
Medical care, 786-798, 1991
|Identification of a candidate therapeutic autophagy-inducing peptide|
S Shoji-Kawata, R Sumpter, M Leveno, GR Campbell, Z Zou, L Kinch, ...
Nature 494 (7436), 201-206, 2013
|Prevalence of psychiatric disorders among men infected with human immunodeficiency virus: a controlled study|
JH Atkinson, I Grant, CJ Kennedy, DD Richman, SA Spector, ...
Archives of General Psychiatry 45 (9), 859-864, 1988
|Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents|
Panel on Clinical Practices for Treatment of HIV Infection
African journal of medical practice 5 (2), 79-104, 1998
|A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection|
SA Bozzette, DM Finkelstein, SA Spector, P Frame, WG Powderly, W He, ...
New England Journal of Medicine 332 (11), 693-699, 1995
|Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome|
RJ Ellis, K Hsia, SA Spector, JA Nelson, RK Heaton, MR Wallace, ...
Annals of neurology 42 (5), 679-688, 1997
|Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial|
RT D'Aquila, MD Hughes, VA Johnson, MA Fischl, JP Sommadossi, ...
Annals of internal medicine 124 (12), 1019-1030, 1996
|A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection|
WG Powderly, DM Finkelstein, J Feinberg, P Frame, W He, ...
New England Journal of Medicine 332 (11), 700-705, 1995
|High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection|
D Havlir, SH Cheeseman, M Mclaughlin, R Murphy, A Erice, SA Spector, ...
Journal of Infectious Diseases 171 (3), 537-545, 1995
|Consensus Development Conference Panel statement: management of hepatitis C|
National Institutes of Health
Viral Hepat Rev 3, 203-217, 1997